Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers
(2010) In Journal of Proteomics 73(6). p.1117-1132- Abstract
- Multiple sclerosis (MS) is a neuro-inflammatory and neurodegenerative disease that results in damage to myelin sheaths and axons in the central nervous system and which preferentially affects young adults. We performed a proteomics-based biomarker discovery study in which cerebrospinal fluid (CSF) from MS and control individuals was analyzed (n=112). Ten candidate biomarkers were selected for evaluation by quantitative immunoassay using an independent cohort of MS and control subjects (n=209). In relapsing remitting MS (ARMS) patients there were significant increases in the CSF levels of alpha-1 antichymotrypsin (A1AC), alpha-1 macroglobulin (A2MG) and fibulin 1 as compared to control subjects. In secondary progressive MS (SPMS) four... (More)
- Multiple sclerosis (MS) is a neuro-inflammatory and neurodegenerative disease that results in damage to myelin sheaths and axons in the central nervous system and which preferentially affects young adults. We performed a proteomics-based biomarker discovery study in which cerebrospinal fluid (CSF) from MS and control individuals was analyzed (n=112). Ten candidate biomarkers were selected for evaluation by quantitative immunoassay using an independent cohort of MS and control subjects (n=209). In relapsing remitting MS (ARMS) patients there were significant increases in the CSF levels of alpha-1 antichymotrypsin (A1AC), alpha-1 macroglobulin (A2MG) and fibulin 1 as compared to control subjects. In secondary progressive MS (SPMS) four additional proteins (contactin 1, fetuin A, vitamin D binding protein and angiotensinogen (ANGT)) were increased as compared to control subjects. In particular, ANGT was increased 3-fold in SPMS, indicating a potential as biomarker of disease progression in MS. In PPMS, A1AC and A2MG exhibit significantly higher CSF levels than controls, with a trend of increase for ANGT. Classification models based on the biomarker panel could identify 70% of the RRMS and 80% of the SPMS patients correctly. Further evaluation was conducted in a pilot study of CSF from RRMS patients (n=36), before and after treatment with natalizumab. (C) 2010 Elsevier B.V. All rights reserved. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1617444
- author
- organization
- publishing date
- 2010
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Treatment, Prognosis, Biomarkers, Proteomics, Multiple sclerosis, CSF
- in
- Journal of Proteomics
- volume
- 73
- issue
- 6
- pages
- 1117 - 1132
- publisher
- Elsevier
- external identifiers
-
- wos:000277763800009
- scopus:77950597049
- pmid:20093204
- ISSN
- 1874-3919
- DOI
- 10.1016/j.jprot.2010.01.004
- language
- English
- LU publication?
- yes
- id
- 481d1f1d-f0cc-4ba7-90d7-caac88204ef9 (old id 1617444)
- date added to LUP
- 2016-04-01 10:58:11
- date last changed
- 2022-05-18 03:36:23
@article{481d1f1d-f0cc-4ba7-90d7-caac88204ef9, abstract = {{Multiple sclerosis (MS) is a neuro-inflammatory and neurodegenerative disease that results in damage to myelin sheaths and axons in the central nervous system and which preferentially affects young adults. We performed a proteomics-based biomarker discovery study in which cerebrospinal fluid (CSF) from MS and control individuals was analyzed (n=112). Ten candidate biomarkers were selected for evaluation by quantitative immunoassay using an independent cohort of MS and control subjects (n=209). In relapsing remitting MS (ARMS) patients there were significant increases in the CSF levels of alpha-1 antichymotrypsin (A1AC), alpha-1 macroglobulin (A2MG) and fibulin 1 as compared to control subjects. In secondary progressive MS (SPMS) four additional proteins (contactin 1, fetuin A, vitamin D binding protein and angiotensinogen (ANGT)) were increased as compared to control subjects. In particular, ANGT was increased 3-fold in SPMS, indicating a potential as biomarker of disease progression in MS. In PPMS, A1AC and A2MG exhibit significantly higher CSF levels than controls, with a trend of increase for ANGT. Classification models based on the biomarker panel could identify 70% of the RRMS and 80% of the SPMS patients correctly. Further evaluation was conducted in a pilot study of CSF from RRMS patients (n=36), before and after treatment with natalizumab. (C) 2010 Elsevier B.V. All rights reserved.}}, author = {{Ottervald, Jan and Franzen, Bo and Nilsson, Kerstin and Andersson, Lars I. and Khademi, Mohsen and Eriksson, Bodil and Kjellstrom, Sven and Marko-Varga, György and Végvári, Ákos and Harris, Robert A. and Laurell, Thomas and Miliotis, Tasso and Matusevicius, Darius and Salter, Hugh and Ferm, Mats and Olsson, Tomas}}, issn = {{1874-3919}}, keywords = {{Treatment; Prognosis; Biomarkers; Proteomics; Multiple sclerosis; CSF}}, language = {{eng}}, number = {{6}}, pages = {{1117--1132}}, publisher = {{Elsevier}}, series = {{Journal of Proteomics}}, title = {{Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers}}, url = {{http://dx.doi.org/10.1016/j.jprot.2010.01.004}}, doi = {{10.1016/j.jprot.2010.01.004}}, volume = {{73}}, year = {{2010}}, }